Versican accumulation drives Nos2 induction and aortic disease in Marfan syndrome via Akt activation
Open Access
- 2 January 2024
- journal article
- research article
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (1) , 132-157
Abstract
Thoracic aortic aneurysm and dissection (TAAD) is a life-threatening condition associated with Marfan syndrome (MFS), a disease caused by fibrillin-1 gene mutations. While various conditions causing TAAD exhibit aortic accumulation of the proteoglycans versican (Vcan) and aggrecan (Acan), it is unclear whether these ECM proteins are involved in aortic disease. Here, we find that Vcan, but not Acan, accumulated in Fbn1 C1041G/+ aortas, a mouse model of MFS. Vcan haploinsufficiency protected MFS mice against aortic dilation, and its silencing reverted aortic disease by reducing Nos2 protein expression. Our results suggest that Acan is not an essential contributor to MFS aortopathy. We further demonstrate that Vcan triggers Akt activation and that pharmacological Akt pathway inhibition rapidly regresses aortic dilation and Nos2 expression in MFS mice. Analysis of aortic tissue from MFS human patients revealed accumulation of VCAN and elevated pAKT-S473 staining. Together, these findings reveal that Vcan plays a causative role in MFS aortic disease in vivo by inducing Nos2 via Akt activation and identify Akt signaling pathway components as candidate therapeutic targets.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (PID2021-122388OB-100)
- Ministerio de Ciencia e Innovación (PID2020-115217RB-100)
- Ministerio de Ciencia e Innovación (RTI2018-099246-B-I00)
- Ministerio de Ciencia e Innovación (CEX2021-001154-S)
- Ministerio de Ciencia e Innovación (CEX2020-001041-S)
- Ministerio de Ciencia e Innovación (BES-2016-077649)
- Ministerio de Ciencia e Innovación (CD18/00028)
- Ministerio de Ciencia e Innovación (IJC2020-044581-I)
- Ministerio de Ciencia e Innovación (RYC2021-033343-I)
- 'la Caixa' Foundation (HR18-00068)
- Instituto de Salud Carlos III (CB16/11/00264)
- Instituto de Salud Carlos III (CB16/11/00479)
- Instituto de Salud Carlos III (PI17/00381)
- Instituto de Salud Carlos III (PI21/00084)
- Fundació la Marató de TV3 (20151330)
- Instituto de Investigación Marqués de Valdecilla (INNVAL 21/24)
- Marfan Foundation (MRF/1701)
- Fundacion MERCK-Fundacion Espanola de Enfermedades Raras (Muévete por los que no pueden 2021)
- Ministerio de Universidades (FPU 20/04814)
This publication has 57 references indexed in Scilit:
- Insufficient versican cleavage and Smad2 phosphorylation results in bicuspid aortic and pulmonary valvesJournal of Molecular and Cellular Cardiology, 2013
- Regulator of calcineurin 1 mediates pathological vascular wall remodelingJournal of Experimental Medicine, 2011
- Pericellular Versican Regulates the Fibroblast-Myofibroblast TransitionJournal of Biological Chemistry, 2011
- Versican V2 Assembles the Extracellular Matrix Surrounding the Nodes of Ranvier in the CNSThe Journal of Neuroscience, 2009
- Heterogeneous transmural proteoglycan distribution provides a mechanism for regulating residual stresses in the aortaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Ultrasound Induces Hypoxia-inducible Factor-1 Activation and Inducible Nitric-oxide Synthase Expression through the Integrin/Integrin-linked Kinase/Akt/Mammalian Target of Rapamycin Pathway in OsteoblastsJournal of Biological Chemistry, 2007
- Overexpression of Transforming Growth Factor-β Is Associated With Increased Hyaluronan Content and Impairment of Repair in Marfan Syndrome Aortic AneurysmCirculation, 2006
- The interaction of versican with its binding partnersCell Research, 2005
- Proteoglycans in Atherosclerosis and RestenosisCirculation Research, 2004
- Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.Journal of Clinical Investigation, 1997